| Company name | ExCulture |
| Year of establishment | 2023 |
| Sector | Horticulture & Food |
| Website | https://exculturebiotech.com/ |
| Status | Active |
ExCulture
ExCulture is a Leiden-based biotech startup developing an animal-free heparin alternative using scalable mixed-culture fermentation to address global heparin shortages. Founded in 2022 and backed by investors including Capricorn Partners and DSM-Firmenich, it aims to replace animal-derived heparin in the US and Europe.
This investment is managed by
Martine Nieuwenhuizen, Investment Manager (TU Delft) at UNIIQ.
